Oct. 16 - Growth of 30% or more in China should compensate for a tough Europe, says Roche CEO Severin Schwan. No comment on talk of a renewed bid for Illumina, but gene-sequencing is a key area.
Swiss drugmaker Roche holdings third quarter sales top forecast rising 15%. 211 point three billion Swiss francs. But pundits continue CEO savage Ron joins me night on the line from Switzerland. Seven thanks for joining us note how I was 2013 shaping up given that sad that recession in many parts of -- is deepening not easing. They let Maine stop off by saying that I'm very pleased that the put. Nine mom or say -- scroll. All of pulpit then it's -- parents both in the opportunity and on the back optics. -- that if you say that different dynamics across different geography it's the Davis. Development in the US. If slightly declining business in Europe and meet the strong double digit growth. It increasingly important the magic pockets and I would expect it Trent called it yet we -- -- to. And. When you talk about imagine -- are you referring specifically to China because there's still a lot of uncertainty. About the direction and the pace of slowing in the Chinese economy. If I spoke if -- speak about the magic pockets really it it across Asia and Latin America is the coveted role. It bowl region in bowl division. But yeah absolutely correct China it's almost the driver and his development -- the accrual of all look that 2%. Poll in farm and then back -- and by what he has strong development as we hopeful look. So growth of both have to percent -- -- 2013. I wouldn't keeping it specific guidance. Put to -- meant the team. But time I'm confident that week and keep the polls that is moment poem. That's been -- the moment the -- followed those and all that pharmaceutical and index -- -- in China. But of course as you well know many of you about your top selling console drugs and treatments are extremely expensive. How risky is this given. Given that they're so expensive and what plans the -- to make them more affordable. Look at actually see it that yet it fixable. Who I so that many of opiates. If you expect that they look at the into the European. Pocket at the -- crash it is the biggest. What we see it at all or -- as a 5% across the industry. And you have experienced the -- special pulpit and over the my -- and -- clearly reflect. Innovation Apollo. -- -- the clinical benefit. All those medic then or pace and so and access that I think -- center in it lip of the issue flop. Look at sponsor ask you about strategy that I know you won't comment specifically on the speculation that you may be back in for that eliminate deal. But is this the kind of deal is this a kind of expansion. Plan that you need to pursue an order to keep shareholders hot topic. Indeed I will common to all of pocket all month. But -- they have said at the they couldn't think clearly all of debate in the area because you think they've been took. And yeah OK -- divide that riot -- all -- this business both intimately. And -- that -- but beyond that that would not comment on any specific. So all of that so there Illumina deal may may or may not be one of those options. Again because I think it's been -- into the sequencing business. You know we have an -- digging tunnel that all -- full five -- we have actually read it to they have mumbled exit incredible pace and but I would call that -- market moments. OKMR strong thank you very much that -- have my thanks to -- CEO seven inch one on the line there from Switzerland. I'm -- be given this is what is.